Signaling Pathway
Enristomig is a monoclonal antibody that targets TNFRSF9 and CD274, designed for precision in immunotherapy research. This antibody binds specifically to TNFRSF9, also known as CD137, and CD274, known as PD-L1, playing a crucial role in modulating immune responses. It is utilized extensively in studies focusing on cancer immunotherapy, autoimmune diseases, and immune checkpoint regulation.
重要通知：仅供研究使用。我们不向患者销售。
| Discription | Enristomig is a monoclonal antibody that targets TNFRSF9 and CD274, designed for precision in immunotherapy research. This antibody binds specifically to TNFRSF9, also known as CD137, and CD274, known as PD-L1, playing a crucial role in modulating immune responses. It is utilized extensively in studies focusing on cancer immunotherapy, autoimmune diseases, and immune checkpoint regulation. |
||
|---|---|---|---|
| Targets |
|
Calculate the dilution required to prepare a stock solution. This equation is commonly abbreviated as: C1V1 = C2V2
